| FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $763.5M | ||||
| Company | Location | Date | Amt. (M) | Details |
| Advanced BioHealing Inc. |
La Jolla, Calif. | 2/28 | $25.5 | Advanced BioHealing completed the Series C round led by Safeguard Scientifics; other investors were Channel Medical Partners, Red Abbey Venture Partners LP, Canaan Partners and Wheatley Partners |
| AlphaVax Inc. | Research Triangle Park, N.C. | 2/2 | $12.7 | AlphaVax completed a $12.7M Series E round with participation from existing investors |
| BiPar Sciences Inc. |
Brisbane, Calif. | 2/26 | $35 | BiPar raised $35M in a Series B led by Domain Associates LLC, with participation from all existing investors, including Vulcan Capital, Canaan Partners, PolyTechnos Venture-Partners, Asset Management Co. and Quantum Technology Partners |
| Cara Therapeutics Inc. |
Tarrytown, N.Y. | 2/22 | $5 | Cara raised another $5M in its Series C, bringing the total to $24M; investors included MVM Life Science Partners, Alta Partners, Ascent Biomedical Ventures, Scottish Widows Investment Partnership and Mitsubishi International Corp. |
| Chimerix Inc. | Research Triangle Park, N.C. | 2/23 | $23 | Chimerix raised $23M in a Series D round led by Canaan Partners, with Alta Partners, Sanderling Ventures, Asset Management Co. and Frazier Healthcare Ventures also participating |
| Circassia Holdings Ltd. |
London | 2/7** | £6 (US$11.7) |
Circassia raised $11.7M in its first formal private funding round since being spun out of Imperial College London in 1998; lead investor was Imperial Innovations plc, with participation from Landsdowne Partners Ltd. and Tudor Capital |
| CoDa Therapeutics Inc. |
San Diego | 2/21 | $10 | CoDa completed the second close of its Series A financing with an additional $10M investment from GBS Venture Partners Ltd. |
| Critical Biologics Corp. |
Cambridge, Mass. | 2/9 | $7 | Critical Biologics closed a $7M Series A round; the investment was provided by Morningside Ventures |
| Genizon BioSciences Inc. |
Montreal | 2/5 | C$10 (US$8.5) |
Genizon raised $8.5M in the first closing of its Series D round; backers include Pfizer Inc. and BTF BV |
| GenTel BioSciences Inc. |
Madison, Wis. | 2/20 | $2 | The financing was led by NEW Capital Fund LP and Wisconsin Investment Partners LLC |
| Ikaria Holdings |
Clinton, N.J. | 2/22 | $300 | The new equity capital was provided to the merged company of Ikaria Inc. and INO Therapeutics Inc. by ARCH Venture Partners, Venrock Associates, Altitude Life Science Ventures, Washington Research Foundation and Alexandria Equities |
| Immatics Biotechnologies GmbH |
Tubingen, Germany | 2/14** | €40 (US$52.1) |
Immatics raised $52.1M in a second round led by DH Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG, with participation from National Technology Enterprises Company, KfW Bankengruppe, 3i plc and Wellington Partners |
| Locus Pharmaceuticals Inc. |
Blue Bell, Pa. | 2/13 | $30.2 | Novartis Bioventures Ltd., Prism Venture Partners and HBM BioVentures (Cayman) Ltd. co-led the financing, with S.R. One Ltd. and L Capital Partners SBIC LP also taking part |
| Omeros Corp. | Seattle | 2/13 | $63 | Omeros raised $63M in a Series E round, which included participation from ARCH Venture Partners, Aravis Ventures, subsidiaries of American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, Trevi Health Ventures and WRF Capital, as well as existing investors |
| Oxford Genome Sciences (UK) Ltd. |
Oxford, UK | 2/5 | ND | Oxford Genome secured the funding through a syndicate of investors, led by Catapult Growth Fund, as well as the South East Growth Fund and Oxford Capital Partners Ltd. |
| Proacta Inc. | San Diego | 2/7 | $35 | The Series B round was led by Clarus Ventures and included participation by Delphi Ventures, Alta Partners, GBS Ventures, Endeavour i-Cap, NO8 Ventures, Genentech Inc. and F. Hoffmann-La Roche Ltd. |
| Regimmune Corp. |
Tokyo | 2/21 | $4.2 | Regimmune raised $4.2M in the first close of its Series B round led by NIF SMBC Ventures Co. Ltd., with participation by Japan Asia Investment Co. Ltd., Mitsubishi UFJ Capital Co. Ltd. and Fund Creation Co. Ltd. |
| Shogoo Pharmaceuticals KK |
Tokyo | 2/2 | 1.6B yen (US$13.6) |
Shogoo raised 1.6 billion yen in a Series A round led by seed investors Atlas Venture and NIF SMBC Co. Ltd. and new investor Nomura Research and Advisory Co. Ltd. |
| Targanta Therapeutics |
Cambridge, Mass. | 2/9 | $70 | Targanta raised $70M in the Series C round led by Brookside Capital, Skyline Ventures, Radius Ventures and OrbiMed Advisors; existing investors Seaflower Ventures, VenGrowth Advanced Life Sciences Fund and the Canadian Medical Discoveries Fund also participated |
| Trellis Biosciences Inc. |
South San Francisco | 2/13 | $10 | Trellis raised $10M in a Series B preferred stock venture capital financing led by Novartis Bioventures Ltd., with participation from Pac- Link Bio Venture Investment Corp. and Saga-more Bioventures LLC, Easton-Hunt Capital Partners LP and Morgenthaler Partners VII LP |
| Trius Therapeutics Inc. |
San Diego | 2/27 | $20 | Trius raised $20M in a Series A round led by Soffinova Ventures |
| Vaccinex Inc. | Rochester, N.Y. | 2/27 | $25 | Vaccinex is raising $25M in a third round with participation from Teva Pharmaceuticals Inc. and Pan Atlantic Bank and Trust Ltd. |
| Notes: | ||||
| Currency conversions are based on exchange rates at the time of the deal. | ||||
| ** Denotes the date the item ran in BioWorld International. | ||||
| ND = Not disclosed. | ||||
